Illumina Announces Three New Sequencers at JPM 2015: HiSeq X Five, HiSeq 3000/4000, and NextSeq 550

Illumina welcomed the new year with three/four new sequencing systems with a wide range of sequencing capabilities. This year Illumina mainly focused of HiSeq X and HiSeq systems and announced new HiSeq X Five, HiSeq 3000/4000, and, NextSeq 550.  Announcing the new set of sequencers, Jay Flatley, Illumina’s Chief Executive Officer, said

Illumina technology has broken down barriers in genomics by increasing data throughput at an astounding rate, while at the same time dramatically reducing the price per data point. These advancements enable us to deliver the industry’s simplest, most efficient sequencing experience to our research and clinical customers as they work to forever transform our understanding of genomics and medicine.

HiSeq X Five System

Illumina HiSeq X Five

Illumina HiSeq X Five Sequencing System

As the name suggests, HiSeq X Five system is a smaller scale HiSeq X Ten system. HiSeq X Five has a set of five HiSeq X machines instead of ten HiSeq X machines. The goal of HiSeq X Five is to offer production-scale sequencing at a lower capitol cost than HiSeq X Ten.  HiSeq X Five can sequence over 9,000 Human genomes in a year.

Illumina HiSeq 3000 and HiSeq 4000

Illumina HiSeq 3000 and HiSeq 4000

Illumina HiSeq 3000 and HiSeq 4000

HiSeq 3000 and HiSeq 4000 are Illumina’s next iteration sequencing system for the current HiSeq 2500.  HiSeq 3000 has single flow cell, while HiSeq 4000 has two flow cells. Illumina brings its patterened flow cell design to the HiSeq 3000 and HiSeq 4000 and makes the to deliver more data at lower cost than the current HiSeq 2500. Illumina claims that the HiSeq 4000 can sequence up to 12 genomes, 100 whole transcriptome samples, or 180 exomes in 3.5 days or less.

Illumina NextSeq 550

Illumina also annouced a new sequencing system NextSeq 550 – combining its current NextSeq 500 and its microarray scanning system. Illumina plans to use NextSeq 550 to a range of applications in “reproductive health, genetic health, and oncology-related research”.

 

Speak Your Mind

*